Zedira's MTG-Handbook


Microbial transglutaminase (MTG) is an enzyme originally produced by Streptomyces species. MTG catalyzes cross-linking of proteins in the absence of calcium. In simple words: MTG is a biological glue. While its physiological role is still not fully understood, MTG received major attraction by the industry for its protein cross-linking activity. It is applied in the production processes of meat, sausage, dairy, bakery, and pasta products to improve food properties.

Moreover, MTG cannot only cross-link proteins, but it can also incorporate primary amines to proteins in a covalent, irreversible manner. This feature allows to link a whole bundle of labels to proteins, including biotin, fluorescent dyes, click chemistry substrates, and cytotoxins.

MTG attracted more and more interest, as developers of antibody drug conjugates realized its unique property to generate site specific and homogenous antibody drug conjugates (ADCs). Today, ADCs manufactured with MTG entered clinical trials.

Zedira’s MTG-Handbook shall provide an overview on this fascinating enzyme. We highly appreciate the blogs of renowned colleagues form the MTG community as part of the handbook. This first edition is just the beginning – future editions will follow to include latest developments and to cover novel applications.

View of Table of Content:
    Editorial
  1. Transglutaminases
  2. MTG – Structure and Numbers.pdf
  3. Biology of Microbial Transglutaminase
  4. Enzymology
  5. The Food Enzyme
  6. The Technical Enzyme
  7. Site Specific Conjugation - ADCs and More.pdf
  8. How to Measure and Detect MTG
  9. MTG-Products and Tools
  10. Application Notes
  11. References

Please feel free to contact us if you would like to receive your personal hard copy of our handbook: contact@zedira.com
MTG-Handbook

Products

  • Zedira offers a huge portfolio of reliable specialist transglutaminase related products meant to catalyze research and development, both in academia and industry.

News  

  • imageReversibly acting transglutaminase 2 inhibitors: drug candidates for the treatment of fibrosis
  • Zedira supports Gordon Research Conference
  • imagePress release: Zedira announces ISO 9001:2015 certification
  • imageZedira communication: Joint poster presentation on “Feasibility of a new automated FXIII activity assay”
  • imageArtikel in DZG Aktuell 01/2019 über die klinische Wirksamkeitsstudie unseres potentiellen Zöliakie Medikaments (deutsch)
  • imagePreview: Catalogue Editorial 2019
  • Press release: Dr. Falk Pharma and Zedira announce start of the phase 2a proof of concept study of ZED1227 for the treatment of celiac disease
  • Artikel in DLG-Lebensmittel – 06/2017 zur Bestimmung von Transglutaminase in Lebensmitteln (deutsch)
  • Zedira publication: Microbial Transglutaminase Used in Bread Preparation at Standard Bakery Concentrations Does Not Increase Immunodetectable Amounts of Deamidated Gliadin
  • Pressemitteilung: Dr. Falk Pharma und Zedira geben den Abschluss der Phase 1b-Studie für ZED1227 zur Zöliakie-Therapie bekannt und planen Start der Wirksamkeitsstudie
  • Press release: Dr. Falk Pharma and Zedira announce completion of phase 1b clinical trial of ZED1227 for the treatment of celiac disease and move on to proof of concept study
  • Press Release: Dr. Falk Pharma GmbH and Zedira enter a phase 1b clinical trial for a celiac disease drug
  • Zedira publication: Microbial transglutaminase has a lower deamidation preference than human tissue transglutaminase on a celiac disease relevant wheat gliadin T-cell epitope
  • Press release: Additional subsidy funding for clinical development of a celiac disease drug
  • Pressemitteilung: Zusätzliche Fördermittel für die klinische Entwicklung eines Zöliakie-Medikamentes
  • Press Release: Cooperation between Zedira and Cardiff University - Transglutaminase 6 is the focus of new research into ataxia
  • Press Release: Dr. Falk Pharma and Zedira enter phase I clinical trials for a celiac disease drug
  • Press release: Zedira receives further funding to develop Factor XIIIa-blockers for safe anticoagulation

Blog  

Events  

  • Canceled and rescheduled: Tampere Celiac Disease Symposium 2020

    18.09.2020 - 19.09.2020
    Tampere, Finland

  • 19th International Celiac Disease Symposium

    14.10.2021 - 17.10.2021
    Sorrento, Italy